Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Otividex in Unilateral Meniere's Disease
NCT03664674Phase 3Completed
- Sponsor
- Otonomy, Inc.
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of Otividex in Meniere's disease (MD), sponsored by Otonomy, Inc.. Started Aug 2018; status: completed.
02
Drugs
Otividex
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT03664674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664674.